Novo Nordisk stock falls just
Photo: Richard Drew/AP/TT

Novo Nordisk stock falls just over 16% after phase 3 results trail Eli Lilly

Danish pharmaceutical giant Novo Nordisk has suffered another setback. The results of a phase 3 study were worse than those of competitor Eli Lilly, and its stock fell just over 16 percent.

Advertisement

The study, called Redefine 4, compared Cagrisema, being developed by Novo Nordisk, with tirzepatide, the active ingredient in competitor Eli Lilly's treatments Mounjaro and Zepbound.

The Danish drug Cagrisema showed a weight loss of 23 percent after 84 weeks, compared with 25.5 percent for Eli Lilly's treatment.

Today's price plunge means Novo Nordisk's stock is trading at its lowest level since 2021. The stock is down nearly 24 percent since the start of the year.

Competitor Eli Lilly's stock was also rising on the New York Stock Exchange. After 1.5 hours of trading, it was up just over 4 percent.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All